Macrolide Antibiotics Market By Drug Type, By Route of Administration, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

The macrolide antibiotics market was valued at $5.6 billion in 2022 and is estimated to reach $7.0 billion by 2032, exhibiting a CAGR of 2.3% from 2023 to 2032. Macrolides are a class of antibiotics, used to treat and manage bacterial infections. These antibiotic compounds have a macrocyclic lactone ring attached with deoxy sugars. Erythromycin was the first macrolide antibiotic developed in 1952 and was used in the treatment of infections in patients allergic to penicillin and also in the case of penicillin resistant infections. Other macrolide antibiotics include roxithromycin, clarithromycin, telithromycin, azithromycin, fidaxomicin and others. The FDA has approved the use of these antibiotics in the treatment of various bacterial infections, which increases their demand in the market.

Macrolide antibiotics act by inhibiting bacterial protein synthesis. These compounds bind to the bacterial 50 S ribosomal subunit, causing the cessation of bacterial protein synthesis. After binding, the drug prevents the translation of mRNA, by inhibiting the enzyme peptidyl transferase from adding the subsequent amino acid attached to the tRNA. Erythromycin is the most used antibiotic, followed by azithromycin and clarithromycin. These antibiotics are active against many strains of bacteria such as streptococci, staphylococci, clostridia, corynebacteria, listeria, haemoplhillus, and others. Erythromycin has a narrow spectrum of activity with action against gram-positive and few gram-negative bacteria. On the other hand, clarithromycin and azithromycin are active against gram-negative bacteria such as helicobacter pylori, taxoplasma gondii and others.

Rise in incidences of bacterial infections around the globe is the major factor driving the growth of the macrolide antibiotics market. There is a significant prevalence of bacterial diseases such as skin infections, respiratory tract infections, sextually transmitted bacterial infection, and others. For instance, according to the WHO, there were an estimated 82.4 million new gonorrhoea infections among adults in 2020. Gonorrhoea is a common sexually transmitted infection having the highest incidence among sex workers, transgender women and adolescents. Thus, rise in incidences of such infections boost the demand for macrolide antibiotics, which contributes to the market growth.

However, rise in antimicrobial resistance among the bacterial species causes hindrance to the market growth. Emergence of macrolide resistant bacteria causes difficulty in treatment of severe infections, which may lead to the death of the patient, increase hospital stay, and increase the cost and expenses related to treatment. As the number of infections caused by macrolide resistant bacteria increases, drugs become ineffective for treatment and thus, there is a reduction in use of available macrolide medications. . This may hinder the growth of the macrolide antibiotics market.

However, a rise in antimicrobial resistance for macrolide class of drug is expected to offer lucrative opportunities for market growth during the forecast period. As bacteria are resistant to the available macrolide antibiotics, there is rise in demand for development of new novel macrolide antibiotics that may help overcome the resistance and thus, are effective in the treatment of severe bacterial infections. This increases R&D activities related to the macrolides and thus, is expected to offer lucrative opportunities for market growth in the coming years.

The macrolide antibiotics market is segmented on the basis of drug type, route or administration, indication, distribution channel, and region. On the basis of drug type, the market is segmented into azithromycin, erythromycin, and others. On the basis of route of administration, the market is classified into oral, parenteral, and others. By indication, the market is segmented into respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers.

By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of AsiaPacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). Major players that operate in the market include Abbott Laboratories, Pfizer Inc., Alkem Laboratories Ltd., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Centurion Healthcare Private Limited, Wellona Pharma, Bristol Laboratories Ltd., and Crescent Pharma Limited.

Key Benefits for Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the macrolide antibiotics market analysis from 2022 to 2032 to identify the prevailing macrolide antibiotics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the macrolide antibiotics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global macrolide antibiotics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Type

Azithromycin
Erythromycin
Others

By Route of Administration

Oral
Parenteral
Others

By Indication

Respiratory Tract Infections
Skin Infections
Sexually Transmitted Infections
Gastrointestinal Infections
Others

By Distribution Channel

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Pfizer Inc.
Teva Pharmaceutical Industries Limited
Wellona Pharma Private Limited.
Sun Pharmaceutical Industries Limited
Bristol Laboratories Ltd.
Zydus Lifesciences Limited
Alkem Laboratories Ltd.
Crescent Pharma Limited
Merck & Co., Inc.
Abbott Laboratories

Product Code: A69591

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in incidences of bacterial infections
  - 3.4.1.2. Availability of generic medications
  - 3.4.1.3. Significant demand for macrolides from emerging countries
- 3.4.2. Restraints
  - 3.4.2.1. Rise in antimicrobial resistance
  - 3.4.2.2. Side effects associated with macrolide antibiotics
- 3.4.3. Opportunities
  - 3.4.3.1. Rise in investments in research and development activities

CHAPTER 4: MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Azithromycin
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Erythromycin
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Oral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Parenteral
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: MACROLIDE ANTIBIOTICS MARKET, BY INDICATION

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Respiratory Tract Infections
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Skin Infections
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Sexually Transmitted Infections
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
6.5. Gastrointestinal Infections
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country
6.6. Others
- 6.6.1. Key market trends, growth factors and opportunities
- 6.6.2. Market size and forecast, by region
- 6.6.3. Market share analysis by country

CHAPTER 7: MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Hospital Pharmacies
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Drug Stores and Retail Pharmacies
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
7.4. Online Providers
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country

CHAPTER 8: MACROLIDE ANTIBIOTICS MARKET, BY REGION

8.1. Overview
- 8.1.1. Market size and forecast By Region
8.2. North America
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by Drug Type
- 8.2.3. Market size and forecast, by Route of Administration
- 8.2.4. Market size and forecast, by Indication
- 8.2.5. Market size and forecast, by Distribution Channel
- 8.2.6. Market size and forecast, by country
  - 8.2.6.1. U.S.
  - 8.2.6.1.1. Market size and forecast, by Drug Type
  - 8.2.6.1.2. Market size and forecast, by Route of Administration
  - 8.2.6.1.3. Market size and forecast, by Indication
  - 8.2.6.1.4. Market size and forecast, by Distribution Channel
  - 8.2.6.2. Canada
  - 8.2.6.2.1. Market size and forecast, by Drug Type
  - 8.2.6.2.2. Market size and forecast, by Route of Administration
  - 8.2.6.2.3. Market size and forecast, by Indication
  - 8.2.6.2.4. Market size and forecast, by Distribution Channel
  - 8.2.6.3. Mexico
  - 8.2.6.3.1. Market size and forecast, by Drug Type
  - 8.2.6.3.2. Market size and forecast, by Route of Administration
  - 8.2.6.3.3. Market size and forecast, by Indication
  - 8.2.6.3.4. Market size and forecast, by Distribution Channel
8.3. Europe
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by Drug Type
- 8.3.3. Market size and forecast, by Route of Administration
- 8.3.4. Market size and forecast, by Indication
- 8.3.5. Market size and forecast, by Distribution Channel
- 8.3.6. Market size and forecast, by country
  - 8.3.6.1. Germany
  - 8.3.6.1.1. Market size and forecast, by Drug Type
  - 8.3.6.1.2. Market size and forecast, by Route of Administration
  - 8.3.6.1.3. Market size and forecast, by Indication
  - 8.3.6.1.4. Market size and forecast, by Distribution Channel
  - 8.3.6.2. France
  - 8.3.6.2.1. Market size and forecast, by Drug Type
  - 8.3.6.2.2. Market size and forecast, by Route of Administration
  - 8.3.6.2.3. Market size and forecast, by Indication
  - 8.3.6.2.4. Market size and forecast, by Distribution Channel
  - 8.3.6.3. UK
  - 8.3.6.3.1. Market size and forecast, by Drug Type
  - 8.3.6.3.2. Market size and forecast, by Route of Administration
  - 8.3.6.3.3. Market size and forecast, by Indication
  - 8.3.6.3.4. Market size and forecast, by Distribution Channel
  - 8.3.6.4. Italy
  - 8.3.6.4.1. Market size and forecast, by Drug Type
  - 8.3.6.4.2. Market size and forecast, by Route of Administration
  - 8.3.6.4.3. Market size and forecast, by Indication
  - 8.3.6.4.4. Market size and forecast, by Distribution Channel
  - 8.3.6.5. Spain
  - 8.3.6.5.1. Market size and forecast, by Drug Type
  - 8.3.6.5.2. Market size and forecast, by Route of Administration
  - 8.3.6.5.3. Market size and forecast, by Indication
  - 8.3.6.5.4. Market size and forecast, by Distribution Channel
  - 8.3.6.6. Rest of Europe
  - 8.3.6.6.1. Market size and forecast, by Drug Type
  - 8.3.6.6.2. Market size and forecast, by Route of Administration
  - 8.3.6.6.3. Market size and forecast, by Indication
  - 8.3.6.6.4. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
- 8.4.1. Key market trends, growth factors and opportunities
- 8.4.2. Market size and forecast, by Drug Type
- 8.4.3. Market size and forecast, by Route of Administration
- 8.4.4. Market size and forecast, by Indication
- 8.4.5. Market size and forecast, by Distribution Channel
- 8.4.6. Market size and forecast, by country
  - 8.4.6.1. Japan
  - 8.4.6.1.1. Market size and forecast, by Drug Type
  - 8.4.6.1.2. Market size and forecast, by Route of Administration
  - 8.4.6.1.3. Market size and forecast, by Indication
  - 8.4.6.1.4. Market size and forecast, by Distribution Channel
  - 8.4.6.2. China
  - 8.4.6.2.1. Market size and forecast, by Drug Type
  - 8.4.6.2.2. Market size and forecast, by Route of Administration
  - 8.4.6.2.3. Market size and forecast, by Indication
  - 8.4.6.2.4. Market size and forecast, by Distribution Channel
  - 8.4.6.3. India
  - 8.4.6.3.1. Market size and forecast, by Drug Type
  - 8.4.6.3.2. Market size and forecast, by Route of Administration
  - 8.4.6.3.3. Market size and forecast, by Indication
  - 8.4.6.3.4. Market size and forecast, by Distribution Channel
  - 8.4.6.4. Australia
  - 8.4.6.4.1. Market size and forecast, by Drug Type
  - 8.4.6.4.2. Market size and forecast, by Route of Administration
  - 8.4.6.4.3. Market size and forecast, by Indication
  - 8.4.6.4.4. Market size and forecast, by Distribution Channel
  - 8.4.6.5. South Korea
  - 8.4.6.5.1. Market size and forecast, by Drug Type
  - 8.4.6.5.2. Market size and forecast, by Route of Administration
  - 8.4.6.5.3. Market size and forecast, by Indication
  - 8.4.6.5.4. Market size and forecast, by Distribution Channel
  - 8.4.6.6. Rest of Asia-Pacific
  - 8.4.6.6.1. Market size and forecast, by Drug Type
  - 8.4.6.6.2. Market size and forecast, by Route of Administration
  - 8.4.6.6.3. Market size and forecast, by Indication
  - 8.4.6.6.4. Market size and forecast, by Distribution Channel
8.5. LAMEA
- 8.5.1. Key market trends, growth factors and opportunities
- 8.5.2. Market size and forecast, by Drug Type
- 8.5.3. Market size and forecast, by Route of Administration
- 8.5.4. Market size and forecast, by Indication
- 8.5.5. Market size and forecast, by Distribution Channel
- 8.5.6. Market size and forecast, by country
  - 8.5.6.1. Brazil
  - 8.5.6.1.1. Market size and forecast, by Drug Type
  - 8.5.6.1.2. Market size and forecast, by Route of Administration
  - 8.5.6.1.3. Market size and forecast, by Indication
  - 8.5.6.1.4. Market size and forecast, by Distribution Channel
  - 8.5.6.2. Saudi Arabia
  - 8.5.6.2.1. Market size and forecast, by Drug Type
  - 8.5.6.2.2. Market size and forecast, by Route of Administration
  - 8.5.6.2.3. Market size and forecast, by Indication
  - 8.5.6.2.4. Market size and forecast, by Distribution Channel
  - 8.5.6.3. South Africa
  - 8.5.6.3.1. Market size and forecast, by Drug Type
  - 8.5.6.3.2. Market size and forecast, by Route of Administration
  - 8.5.6.3.3. Market size and forecast, by Indication
  - 8.5.6.3.4. Market size and forecast, by Distribution Channel
  - 8.5.6.4. Rest of LAMEA
  - 8.5.6.4.1. Market size and forecast, by Drug Type
  - 8.5.6.4.2. Market size and forecast, by Route of Administration
  - 8.5.6.4.3. Market size and forecast, by Indication
  - 8.5.6.4.4. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

10.1. Abbott Laboratories
- 10.1.1. Company overview
- 10.1.2. Key executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Business performance
10.2. Pfizer Inc.
- 10.2.1. Company overview
- 10.2.2. Key executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.2.6. Business performance
10.3. Alkem Laboratories Ltd.
- 10.3.1. Company overview
- 10.3.2. Key executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Business performance
10.4. Sun Pharmaceutical Industries Limited
- 10.4.1. Company overview
- 10.4.2. Key executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.6. Business performance
10.5. Teva Pharmaceutical Industries Limited
- 10.5.1. Company overview
- 10.5.2. Key executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
- 10.5.6. Business performance
- 10.5.7. Key strategic moves and developments
10.6. Wellona Pharma Private Limited.
- 10.6.1. Company overview
- 10.6.2. Key executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
10.7. Bristol Laboratories Ltd.
- 10.7.1. Company overview
- 10.7.2. Key executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
10.8. Crescent Pharma Limited
- 10.8.1. Company overview
- 10.8.2. Key executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
10.9. Merck & Co., Inc.
- 10.9.1. Company overview
- 10.9.2. Key executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.9.6. Business performance
- 10.9.7. Key strategic moves and developments
10.10. Zydus Lifesciences Limited
- 10.10.1. Company overview
- 10.10.2. Key executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- 10.10.6. Business performance
- 10.10.7. Key strategic moves and developments